Ataluren for the treatment of nonsense-mutation cystic fibrosis: a randomised, double-blind, placebo-controlled phase 3 trial
- Submitting institution
-
Queen's University of Belfast
- Unit of assessment
- 3 - Allied Health Professions, Dentistry, Nursing and Pharmacy
- Output identifier
- 92607657
- Type
- D - Journal article
- DOI
-
10.1016/S2213-2600(14)70100-6
- Title of journal
- The Lancet Respiratory Medicine
- Article number
- -
- First page
- 539
- Volume
- 2
- Issue
- 7
- ISSN
- 2213-2600
- Open access status
- Out of scope for open access requirements
- Month of publication
- May
- Year of publication
- 2014
- URL
-
-
- Supplementary information
-
-
- Request cross-referral to
- -
- Output has been delayed by COVID-19
- No
- COVID-19 affected output statement
- -
- Forensic science
- No
- Criminology
- No
- Interdisciplinary
- No
- Number of additional authors
-
25
- Research group(s)
-
D - WWIEM
- Citation count
- 205
- Proposed double-weighted
- No
- Reserve for an output with double weighting
- No
- Additional information
- -
- Author contribution statement
- The author made a substantial contribution to the conception and design of the study; to the organisation of the conduct of the study; and to analysis and interpretation of study data and helped draft the output
- Non-English
- No
- English abstract
- -